NCT07462507 2026-03-10
Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Washington University School of Medicine
Phase 2 Not yet recruiting
Clinical Trials
69 trialsNCT07439172 2026-02-27
PRC
The Cooper Health System
Phase 2 Not yet recruiting
NCT05345002 2026-02-20
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT04623931 2026-01-14
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06439420 2025-10-01
CBT-I in PBT
Virginia Commonwealth University
Phase 2 Completed
NCT03180502 2025-07-11
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
NRG Oncology
Phase 2 Active not recruiting
NCT03220646 2025-07-09
Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05297864 2025-05-23
OU-SCC-PI-4G
University of Oklahoma
Phase 2 Terminated
NCT02530320 2024-11-22
Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved
Grupo Español de Investigación en Neurooncología
Phase 2 Completed
NCT03969706 2024-11-18
Abemaciclib in Patients with Oligodendroglioma
Abramson Cancer Center at Penn Medicine
Phase 2 Active not recruiting
NCT02372409 2024-11-01
Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
Washington University School of Medicine
Phase 2 Terminated
NCT00445965 2024-04-04
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02023905 2022-12-29
Everolimus With and Without Temozolomide in Adult Low Grade Glioma
University of California, San Francisco
Phase 2 Terminated
NCT05512351 2022-09-27
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma
Henan Provincial People's Hospital
Phase 2 Recruiting
NCT00003458 2022-03-07
Antineoplaston Therapy in Treating Children With Brain Tumors
Burzynski Research Institute
Phase 2 Completed
NCT01032200 2021-09-28
Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors
Wake Forest University Health Sciences
Phase 2 Completed
NCT00070161 2021-09-09
Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor
Wake Forest University Health Sciences
Phase 2 Completed
NCT00079092 2021-09-09
Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma
Wake Forest University Health Sciences
Phase 2 Completed
NCT04755023 2021-02-15
TEMOBIC
Assistance Publique Hopitaux De Marseille
Phase 2 Completed
NCT01635283 2020-11-04
Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00823459 2020-07-28
Everolimus in Treating Patients With Recurrent Low-Grade Glioma
University of California, San Francisco
Phase 2 Completed
NCT03014804 2020-07-24
Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT00795665 2020-05-12
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
University of California, Davis
Phase 2 Completed
NCT01478321 2020-03-12
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
Northwestern University
Phase 2 Terminated
NCT00276783 2020-03-05
Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases
Northwestern University
Phase 2 Unknown
NCT00892177 2019-10-21
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01966809 2019-08-20
Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
Medical College of Wisconsin
Phase 2 Terminated
NCT00243022 2019-04-30
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT02209428 2019-02-21
A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas
Huashan Hospital
Phase 2 Unknown
NCT00313729 2019-02-07
Temozolomide in Treating Patients With Low-Grade Glioma
University of California, San Francisco
Phase 2 Completed
NCT00400816 2018-09-18
Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma
The Cleveland Clinic
Phase 2 Completed
NCT00058123 2018-08-21
Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00006080 2018-06-27
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00025675 2018-06-26
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00619112 2018-01-31
Temozolomide in Treating Patients With Recurrent High-Grade Glioma
University of California, San Francisco
Phase 2 Completed
NCT02977689 2017-12-20
Trial of IDH305 in IDH1 Mutant Grade II or III Glioma
NYU Langone Health
Phase 2 Withdrawn
NCT00362570 2017-11-30
Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00047281 2017-07-11
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00823797 2017-07-07
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
University of Washington
Phase 2 Completed
NCT00360828 2017-03-23
Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01847235 2016-04-26
Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial
Seoul National University Hospital
Phase 2 Completed
NCT00498927 2016-02-29
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01663012 2016-02-24
Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
Stanford University
Phase 2 Completed
NCT00006263 2015-08-05
Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma
NYU Langone Health
Phase 2 Withdrawn
NCT01380782 2014-08-18
BIBF 1120 for Recurrent High-Grade Gliomas
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00352521 2014-07-22
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma
Duke University
Phase 2 Completed
NCT00268359 2014-07-21
Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas
Duke University
Phase 2 Completed
NCT00003466 2014-07-09
Temozolomide in Treating Patients With Progressive Low-Grade Glioma
Duke University
Phase 2 Completed
NCT00274755 2014-05-20
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas
University of California, San Francisco
Phase 2 Completed
NCT01403311 2014-03-26
ALA
Legacy Health System
Phase 2 Unknown